Docosahexaenoic acid incorporation into erythrocyte membrane (DHA incorporation)

Docosahexaenoic acid incorporation into the erythrocyte membrane refers to the physiological process by which dietary or endogenously synthesized docosahexaenoic acid (DHA), an omega‐3 polyunsaturated fatty acid, becomes integrated into the phospholipid bilayer of red blood cells. This process reflects long-term intake and status of omega‐3 fatty acids in the body. The level of DHA in erythrocyte membranes is used as part of the "omega‐3 index," which serves as a biomarker for cardiovascular risk assessment and other health outcomes. Higher levels are associated with improved cardiovascular health, better neurodevelopmental outcomes in infants, and may be inversely related to severity in conditions like obstructive sleep apnea. However, "incorporation" itself is not a therapeutic target but rather describes a biological state or marker resulting from dietary intake or supplementation with omega‐3 fatty acids such as fish oil. Note: This entry does not correspond to a single protein/gene/receptor/enzyme but rather describes a metabolic outcome/process; therefore it should not be considered an individual druggable target according to standard pharmacological definitions.

Other names

DHA incorporation into red blood cell membraneErythrocyte DHA contentOmega-3 index (when referring to combined EPA+DHA in erythrocytes)